ATE344665T1 - Verfahren zur herstellung einer einen antiretroviralen proteasehemmer enthaltenden pharmazeutischen zusammensetzung mit verbesserter bioverfügbarkeit - Google Patents
Verfahren zur herstellung einer einen antiretroviralen proteasehemmer enthaltenden pharmazeutischen zusammensetzung mit verbesserter bioverfügbarkeitInfo
- Publication number
- ATE344665T1 ATE344665T1 AT03710082T AT03710082T ATE344665T1 AT E344665 T1 ATE344665 T1 AT E344665T1 AT 03710082 T AT03710082 T AT 03710082T AT 03710082 T AT03710082 T AT 03710082T AT E344665 T1 ATE344665 T1 AT E344665T1
- Authority
- AT
- Austria
- Prior art keywords
- improved bioavailability
- protease inhibitor
- producing
- pharmaceutical composition
- composition containing
- Prior art date
Links
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 title abstract 2
- 230000000798 anti-retroviral effect Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 abstract 3
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 abstract 3
- 229940075559 piperine Drugs 0.000 abstract 3
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 abstract 3
- 235000019100 piperine Nutrition 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 abstract 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 abstract 1
- 229960001830 amprenavir Drugs 0.000 abstract 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229960001936 indinavir Drugs 0.000 abstract 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229960004525 lopinavir Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960000884 nelfinavir Drugs 0.000 abstract 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 229960001852 saquinavir Drugs 0.000 abstract 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN325MU2002 | 2002-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE344665T1 true ATE344665T1 (de) | 2006-11-15 |
Family
ID=28687129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03710082T ATE344665T1 (de) | 2002-04-04 | 2003-04-04 | Verfahren zur herstellung einer einen antiretroviralen proteasehemmer enthaltenden pharmazeutischen zusammensetzung mit verbesserter bioverfügbarkeit |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1494749B1 (de) |
| AT (1) | ATE344665T1 (de) |
| AU (1) | AU2003214505A1 (de) |
| DE (1) | DE60309582T2 (de) |
| EA (1) | EA009214B1 (de) |
| ES (1) | ES2277067T3 (de) |
| GB (1) | GB2403411B (de) |
| WO (1) | WO2003084462A2 (de) |
| ZA (1) | ZA200408929B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| RU2012104843A (ru) * | 2009-07-23 | 2013-08-27 | Кадила Фармасьютикалз Лтд. | Фармацевтическая композиция рифампицина |
| GB201006038D0 (en) | 2010-04-12 | 2010-05-26 | Unilever Plc | Improvements relating to antiviral compositions |
| ES2902136T3 (es) | 2016-02-12 | 2022-03-25 | Cipla Ltd | Composiciones farmacéuticas que comprenden un fármaco antirretrovírico y un potenciador farmacocinético |
| CN110769856A (zh) * | 2017-04-18 | 2020-02-07 | 希普拉有限公司 | 用于治疗逆转录病毒感染的组合疗法 |
| EP3773731A1 (de) * | 2018-04-05 | 2021-02-17 | Cipla Limited | Pharmazeutische formulierungen |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN176897B (de) * | 1993-10-29 | 1996-09-28 | Cadila Lab Ltd | |
| US5744161A (en) * | 1995-02-24 | 1998-04-28 | Sabinsa Corporation | Use of piperine as a bioavailability enhancer |
| IN186315B (de) * | 1996-12-12 | 2001-08-04 | Panacea Biotec Ltd |
-
2003
- 2003-04-04 AU AU2003214505A patent/AU2003214505A1/en not_active Abandoned
- 2003-04-04 EP EP03710082A patent/EP1494749B1/de not_active Expired - Lifetime
- 2003-04-04 AT AT03710082T patent/ATE344665T1/de not_active IP Right Cessation
- 2003-04-04 DE DE60309582T patent/DE60309582T2/de not_active Expired - Lifetime
- 2003-04-04 ES ES03710082T patent/ES2277067T3/es not_active Expired - Lifetime
- 2003-04-04 GB GB0423763A patent/GB2403411B/en not_active Expired - Fee Related
- 2003-04-04 EA EA200401580A patent/EA009214B1/ru not_active IP Right Cessation
- 2003-04-04 WO PCT/IB2003/001222 patent/WO2003084462A2/en active IP Right Grant
-
2004
- 2004-11-04 ZA ZA200408929A patent/ZA200408929B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60309582D1 (de) | 2006-12-21 |
| GB2403411B (en) | 2006-04-12 |
| ZA200408929B (en) | 2006-07-26 |
| EA009214B1 (ru) | 2007-12-28 |
| GB0423763D0 (en) | 2004-12-01 |
| EP1494749A2 (de) | 2005-01-12 |
| AU2003214505A1 (en) | 2003-10-20 |
| AU2003214505A8 (en) | 2003-10-20 |
| EA200401580A1 (ru) | 2005-12-29 |
| EP1494749B1 (de) | 2006-11-08 |
| WO2003084462A3 (en) | 2003-12-24 |
| WO2003084462A2 (en) | 2003-10-16 |
| GB2403411A (en) | 2005-01-05 |
| DE60309582T2 (de) | 2007-09-13 |
| ES2277067T3 (es) | 2007-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008017867A3 (en) | Antiretroviral solid oral composition with at least one water insoluble polymer | |
| MX2023015533A (es) | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. | |
| MX2007004987A (es) | Nuevas formulaciones de tabletas de liberacion modificada para inhibidores de bomba de protones. | |
| HUP0401224A2 (hu) | Eljárás gyógyászati készítmények előállítására lágyzselatin-összetételekkel való felhasználás céljára | |
| ATE486587T1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
| AR036813A1 (es) | Composiciones farmaceuticas | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
| HK1119596A1 (en) | Use of yrazolopyrimidinone derivative in the preparation of agent for the prevention and treatment of liver diseases | |
| ATE453382T1 (de) | Pulver zur nasalen verabreichung von wirkstoffen | |
| TN2009000504A1 (en) | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray | |
| DE60309582D1 (de) | Verfahren zur herstellung einer einen antiretroviralen proteasehemmer enthaltenden pharmazeutischen zusammensetzung mit verbesserter bioverfügbarkeit | |
| MX2009006699A (es) | Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos. | |
| EA200600377A1 (ru) | Новая композиция | |
| WO2008077772A3 (en) | Combination of a retinoid and a platinum anticancer agent | |
| ATE451385T1 (de) | Verbindungen zur inhibierung von apoptose | |
| KR960700701A (ko) | 파라세타몰 및 l-시스테인 또는 이것의 전구물질을 함유하는 약제조성물(pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof) | |
| MX2022015232A (es) | Composicion farmaceutica acuosa de levilimab y su uso. | |
| EA200301129A1 (ru) | Ингибирование ароматазы для улучшения вспомогательной репродукции | |
| DK2091520T3 (da) | Oral doseringsform omfattende trisubstituerede glycerol-forbindelser | |
| ATE301452T1 (de) | Verfahren zur herstellung einer flüssigen dosierungseinheit und kit | |
| JP2018177697A (ja) | 固形組成物 | |
| CN106913535A (zh) | 一种ddp-4抑制剂药物口崩片及其制备方法 | |
| UA120764U (uk) | Лікарський препарат знеболювальної та спазмолітичної дії "фентаніл" | |
| AR034701A1 (es) | Nuevas composiciones farmaceuticas con accion antidiabetica y proceso para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |